US federal authorities have charged the owner of American Premier Labs with a $93 million healthcare fraud scheme involving false genetic testing claims. The accused has reportedly fled to Hyderabad, India, as authorities work to recover funds. This case highlights rising regulatory scrutiny over medical billing and diagnostic testing practices.
Federal prosecutors in the United States have leveled serious charges against Khadeer Khan Mohammed, the owner of the Texas-based American Premier Labs LLC, for allegedly orchestrating a massive Medicare fraud scheme. Authorities claim the lab submitted approximately $93 million in fraudulent claims to the U.S. government-funded Medicare program between August 2023 and October 2024, with the system paying out at least $63 million based on these filings.
Nature of the Alleged Scheme
The indictment details a sophisticated method of exploitation involving the unauthorized use of medical professionals' credentials. Prosecutors allege that Mohammed used the identities of doctors without their permission to bill for genetic tests that were neither medically necessary nor ever performed. The scheme reportedly targeted Medicare beneficiaries who had no existing treatment relationship with the physicians listed on the claim forms. This type of billing fraud, where medical providers are billed for services that did not happen, is a major focus area for US healthcare regulators.
Fugitive Status and International Legal Hurdles
Following the discovery of the alleged fraud, US federal agents successfully seized approximately $6 million from bank accounts linked to Mohammed. Despite these enforcement actions, Mohammed remains at large. US authorities have officially declared him a fugitive, with evidence indicating that he has left the United States and is currently residing in Hyderabad, India. This has complicated the legal proceedings, as federal agencies now face the challenge of navigating international jurisdictions to pursue the case and recover the remaining misappropriated funds.
Sector Risk and Regulatory Scrutiny
While American Premier Labs LLC is a private entity, this case serves as a stark reminder of the regulatory risks facing the global diagnostic and genetic testing sector. The healthcare industry, particularly in the US, is currently witnessing a period of intense audit and compliance focus. Governments are increasingly using advanced data analytics to flag suspicious billing patterns, such as the sudden spikes in genetic testing claims that triggered the investigation into this case.
For investors monitoring the broader healthcare services and diagnostics space, the takeaway is clear: regulatory compliance and billing transparency are more critical than ever. Cases involving significant financial fraud often lead to stricter oversight, updated billing guidelines, and more frequent audits for laboratories and healthcare providers. Companies with robust internal controls and transparent revenue models are generally better positioned to navigate this tougher regulatory environment.
The next major updates will involve international efforts by US federal authorities to address the fugitive status of the accused and potential civil or criminal proceedings regarding the recovery of the remaining $57 million in Medicare payouts.